Novel formulations derived from this platform are particularly suited for (chronic) inflammatory diseases as it leaves non-target organs and locations unaffected, preventing the side effects associated with contemporary immunosuppressive medication. To prove the value of these new and targeted therapeutics, Mercurna is initially focusing on the development of mCura1 as a candidate treatment for inflammation in the kidney. As such, mCura1 will be suitable for various kidney diseases underlying chronic kidney disease.